Early Retiree
Research analyst, value, small-cap, retirement and income

Stallergenes: An Unknown, Predictable Biotech With 50% Upside

(Editors' Note: Stallergenes trades on the Paris Stock Exchange under the ticker symbol GENP.PA, with €300K average daily volume).

The company

With about 27% share of the $1.2 billion immunotherapy market, French biotech Stallergenes (OTC:STLEF) is one of the two world market leaders in the field of desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis, rhinitis and allergic asthma. Stallergenes is present in almost 40 countries via ten subsidiaries in Europe in Germany, Italy, Spain, Belgium, Switzerland, the Netherlands, the Czech Republic, Slovakia, Austria and Great Britain, and has entered into numerous partnerships and distribution agreements. Stallergenes has recently accelerated its global expansion by offering Oralair, the first ever immunotherapy tablet...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details